Key Highlights
- VivoSim Labs has signed a seven-figure agreement with a top-10 global pharmaceutical company for NAMkind liver and intestinal toxicology testing.
- The company now expects fiscal 2027 Revenue to exceed its previously issued guidance of 500%+ growth.
- Revenue from the agreement is expected to be recognized in VivoSim's fiscal Q3 and Q4, ending December 31 and March 31 respectively.
- The NAMkind Liver model predicted drug-induced liver injury with 91% accuracy across a 92-compound clinical dataset, compared to 50-65% for animal models.
VivoSim Labs, Inc. (NASDAQ:VIVS), a provider of next-generation 3D human cellular models for preclinical safety and efficacy testing, has announced a seven-figure agreement with a top-10 global pharmaceutical company for its NAMkind testing services. With this agreement, the company now expects fiscal 2027 revenue to exceed the guidance of 500%+ growth it issued on July 15, 2026.
The agreement covers NAMkind liver and intestinal toxicology testing, with work already underway. Revenue is expected to be recognized in VivoSim's fiscal Q3 and Q4, ending December 31 and March 31 respectively. Following this program, VivoSim anticipates that NAMkind testing will become part of the customer's regular flow of ongoing preclinical work.
How Do Large Pharmaceutical Companies Adopt New Testing Methods?
VivoSim described the typical adoption process for large pharmaceutical companies. A company with over $10 billion in annual revenue does not quickly change how it tests drug candidates and requires extensive scientific due diligence. It then runs a new model on compounds whose clinical outcomes are already known, compares results with what animal studies showed, and only then commits to live program work. The agreement announced covers that program work stage.
Executive Chairman Keith Murphy stated that the Quarterly Report filed recently shows both toxicology businesses growing, and that this agreement alone is expected to take the company past the 500% growth number. He emphasized that what matters more is what comes after, noting that the company expects the customer's regular testing to follow.
What Is the NAMkind Technology Platform?
NAMkind liver and intestine models are built from primary human cells and dosed repeatedly over weeks. Across a clinical dataset of 92 small-molecule compounds, the NAMkind Liver model predicted drug-induced liver injury with 91% accuracy, 90% sensitivity, and 95% specificity. Animal models and traditional methods typically detect 50% to 65% of true liver toxicants.
In September 2026, the U.S. Food and Drug Administration issued a direct final rule clarifying that non-animal methods may be used, where appropriate, to test the safety of drugs and biologics. This regulatory development provides a supportive backdrop for companies like VivoSim that offer non-animal testing alternatives.
What Is the Growth Pipeline Beyond This Deal?
VivoSim reported that both liver and intestinal toxicology businesses grew in the quarter ended September 30, 2026, with orders from both large pharmaceutical companies and smaller biotechs. The company also recently added efficacy testing capabilities and entered a collaboration with Chemveda Life Sciences for AI-designed compound testing.


_11_20_2026_20_27_34_097200.jpg)



Please wait processing your request...